Low blood eosinophil counts are not always a reliable marker of clinical response to mepolizumab in severe asthma

被引：13

作者：

Ojanguren, Inigo ^{[1
,2
]}

Chaboillez, Simone ^{[1
]}

Lemiere, Catherine ^{[1
]}

机构：

[1] Univ Montreal, Hop Sacre Coeur Montreal, Ctr Integre Univ Sante & Serv Sociaux Nord de Ile, Montreal, PQ, Canada

[2] Inst Salud Carlos III, CIBER Enfermedades Resp CIBERES, Barcelona, Spain

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | 2018年 / 6卷 / 06期

关键词：

MULTICENTER; DREAM;

D O I：

10.1016/j.jaip.2018.04.014

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

[No abstract available]

引用

页码：2151 / 2153

页数：3

共 9 条

[1] Severe Asthma Phenotypes - How Should They Guide Evaluation and Treatment? [J].

Fitzpatrick, Anne M. ;

Moore, Wendy C. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2017, 5 (04) :901-908

[2] Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma [J].

Kelly, Elizabeth A. ;

Esnault, Stephane ;

Liu, Lin Ying ;

Evans, Michael D. ;

Johansson, Mats W. ;

Mathur, Sameer ;

Mosher, Deane F. ;

Denlinger, Loren C. ;

Jarjour, Nizar N. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 196 (11) :1385-1395

[3] Airway inflammation assessed by invasive and noninvasive means in severe asthma:: Eosinophilic and noneosinophilic phenotypes [J].

Lemiere, Catherine ;

Ernst, Pierre ;

Olivenstein, Ron ;

Yamauchi, Yasuhiro ;

Govindaraju, Karuthapillai ;

Ludwig, Mara S. ;

Martin, James G. ;

Hamid, Gutayba .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (05) :1033-1039

[4] Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study [J].

Lugogo, Njira ;

Domingo, Christian ;

Chanez, Pascal ;

Leigh, Richard ;

Gilson, Martyn J. ;

Price, Robert G. ;

Yancey, Steven W. ;

Ortega, Hector G. .

CLINICAL THERAPEUTICS, 2016, 38 (09) :2058-2070

[5] Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab [J].

Mukherjee, Manali ;

Paramo, Fernando Aleman ;

Kjarsgaard, Melanie ;

Salter, Brittany ;

Nair, Gayatri ;

LaVigne, Nicola ;

Radford, Katherine ;

Sehmi, Roma ;

Nair, Parameswaran .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (01) :38-46

[6] Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies [J].

Ortega, Hector G. ;

Yancey, Steven W. ;

Mayer, Bhabita ;

Gunsoy, Necdet B. ;

Keene, Oliver N. ;

Bleecker, Eugene R. ;

Brightling, Christopher E. ;

Pavord, Ian D. .

LANCET RESPIRATORY MEDICINE, 2016, 4 (07) :549-556

[7] Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial [J].

Pavord, Ian D. ;

Korn, Stephanie ;

Howarth, Peter ;

Bleecker, Eugene R. ;

Buhl, Roland ;

Keene, Oliver N. ;

Ortega, Hector ;

Chanez, Pascal .

LANCET, 2012, 380 (9842) :651-659

[8]

SCHLEICH FN, 2014, EUR RESPIR J, V44, P1098, DOI DOI 10.1183/09031936.00118014

[9] Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma [J].

Sehmi, R. ;

Smith, S. G. ;

Kjarsgaard, M. ;

Radford, K. ;

Boulet, L. -P. ;

Lemiere, C. ;

Prazma, C. M. ;

Ortega, H. ;

Martin, J. G. ;

Nair, P. .

CLINICAL AND EXPERIMENTAL ALLERGY, 2016, 46 (06) :793-802

← 1 →